Offerpad Solutions Inc. Form 8-K Summary
Business Context and Reporting Period
Offerpad Solutions Inc. filed a Form 8-K regarding a New York Stock Exchange (NYSE) continued-listing deficiency. The earliest reported event occurred on November 15, 2022; the report was signed November 18, 2022. The filing does not report quarterly or annual operating results.
Financial Metrics and Liquidity
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics. The filing text does not provide a clear value for the Company’s stock price or the duration of the deficiency beyond stating that the average closing price was below $1.00 over a consecutive 30-trading-day period.
Material Changes and Listing Status
- On November 15, 2022, the NYSE notified the Company that it was not in compliance with Section 802.01C of the NYSE Listed Company Manual because its Class A common stock had an average closing price below $1.00 over 30 consecutive trading days.
- The notice did not immediately delist the Company’s Class A common stock, which continued trading on the NYSE subject to compliance with other listing standards.
- The Company notified the NYSE on November 16, 2022 that it intended to cure the deficiency.
- The Company had six months from receipt of the notice to regain compliance. Generally, compliance requires a closing price of at least $1.00 and a 30-trading-day average closing price of at least $1.00 on the last trading day of a calendar month during the cure period.
- The Company stated that it may consider alternatives, including a reverse stock split requiring stockholder approval, if necessary.
Outlook, Risks, and Unusual Items
Management expressed an intention to pursue available alternatives to restore compliance but did not provide financial guidance. If an action requiring stockholder approval at the next annual meeting is used, NYSE rules may deem the deficiency cured if the share price promptly exceeds $1.00 and remains above that level for at least 30 trading days.
Key risks include the Company’s ability to regain compliance within the applicable cure period, maintain compliance with other NYSE listing standards, obtain any required stockholder approval, and avoid potential delisting. The filing also refers investors to the risk factors in the Company’s 2021 Form 10-K and other SEC reports.
Important Facts to Verify
- Whether the Company regained compliance with the NYSE $1.00 price requirement within the six-month cure period.
- Whether the Company pursued or completed a reverse stock split or another corrective action.
- Whether the NYSE imposed additional conditions or ultimately initiated delisting proceedings.
- The Company’s contemporaneous cash position, operating performance, debt obligations, and liquidity, which are not disclosed in this filing.
- The November 18, 2022 press release furnished as Exhibit 99.1 and subsequent SEC filings for developments after this notice.